Published in Cell Signal on July 13, 2007
Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal (2008) 1.28
Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim Biophys Acta (2012) 1.06
Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs. Am J Physiol Lung Cell Mol Physiol (2011) 1.05
Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation. Cell Commun Signal (2009) 1.05
Lysophosphatidic acid enhances pulmonary epithelial barrier integrity and protects endotoxin-induced epithelial barrier disruption and lung injury. J Biol Chem (2009) 1.02
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget (2014) 0.96
Role of acylglycerol kinase in LPA-induced IL-8 secretion and transactivation of epidermal growth factor-receptor in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2008) 0.96
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem (2014) 0.94
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J (2011) 0.91
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Am J Physiol Lung Cell Mol Physiol (2013) 0.83
Enhanced PKCδ and ERK signaling mediate cell migration of retinal pigment epithelial cells synergistically induced by HGF and EGF. PLoS One (2012) 0.81
Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface. Cell Signal (2014) 0.79
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol (1999) 2.86
Lysophospholipids--receptor revelations. Science (2001) 2.61
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J (2004) 2.38
A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res (2006) 2.01
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic (2001) 1.89
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta (1993) 1.76
Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol (1994) 1.64
Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem (2004) 1.59
Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells--regulation by Rho, Rac and Rab small G proteins. Oncogene (1999) 1.57
Endosomal dynamics of Met determine signaling output. Mol Biol Cell (2003) 1.55
Get off my back! Rapid receptor internalization through circular dorsal ruffles. Cancer Res (2006) 1.55
Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene (2001) 1.52
PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J (2004) 1.51
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci (2001) 1.42
Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J (2006) 1.34
Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J (2005) 1.27
Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol (2006) 1.27
Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem (2004) 1.25
Lysophospholipid receptors in the nervous system. Neurochem Res (2002) 1.17
G protein-coupled time travel: evolutionary aspects of GPCR research. Mol Interv (2007) 1.16
Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun (1999) 1.15
Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells. J Biol Chem (2003) 1.12
LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem (2006) 1.12
Increased protein kinase C activity is linked to reduced insulin receptor autophosphorylation in liver of starved rats. J Biol Chem (1990) 1.11
Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J Biol Chem (2004) 1.10
Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett (2004) 1.09
Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. J Biol Chem (1991) 1.04
Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells. J Biol Chem (2007) 1.00
Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. J Biol Chem (1991) 1.00
Lysophospholipid receptor nomenclature. Biochim Biophys Acta (2002) 0.99
Steroids as regulators of the mammalian immune response. J Invest Dermatol (1995) 0.99
Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors. Curr Pharm Des (2004) 0.98
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. World J Gastroenterol (2005) 0.98
MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor. Mol Cell Biochem (2005) 0.95
PKCdelta-mediated IRS-1 Ser24 phosphorylation negatively regulates IRS-1 function. Biochem Biophys Res Commun (2006) 0.91
Signal transduction pathways of G protein-coupled receptors and their cross-talk with receptor tyrosine kinases: lessons from bradykinin signaling. Curr Med Chem (2000) 0.90
HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells. Int J Mol Med (2001) 0.89
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol (2003) 0.84
Stimulation of the alpha1A adrenergic receptor inhibits PDGF-induced PDGF beta receptor Tyr751 phosphorylation and PI 3-kinase activation. FEBS Lett (2003) 0.83
Receptor tyrosine kinase-G-protein coupled receptor complex signaling in mammalian cells. Adv Enzyme Regul (2007) 0.82
Internalization and degradation of hepatocyte growth factor in hepatocytes with down-regulation of the receptor/c-Met. FEBS Lett (1993) 0.81
Molecular understanding of cytokine-steroid hormone dialogue: implications for human diseases. Ann N Y Acad Sci (2006) 0.80
Rottlerin induces a transformed phenotype in human keratinocytes. Biochem Biophys Res Commun (2001) 0.77
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med (2005) 4.31
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol (2002) 2.18
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. Anal Biochem (2005) 1.77
Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1. J Biol Chem (2007) 1.74
Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. J Cell Physiol (2004) 1.70
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol (2003) 1.64
Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid Redox Signal (2009) 1.64
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem (2004) 1.59
Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells. J Biol Chem (2005) 1.57
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51
Involvement of microtubules and Rho pathway in TGF-beta1-induced lung vascular barrier dysfunction. J Cell Physiol (2005) 1.50
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50
De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells. Cell Signal (2006) 1.50
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation. Am J Physiol Cell Physiol (2014) 1.46
FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J Biol Chem (2009) 1.46
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J Biol Chem (2006) 1.44
The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem (2010) 1.42
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J (2009) 1.38
Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol (2009) 1.36
Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid Redox Signal (2009) 1.36
Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med (2006) 1.36
Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J (2006) 1.34
Signal transduction of phorbol 12-myristate 13-acetate (PMA)-induced growth inhibition of human monocytic leukemia THP-1 cells is reactive oxygen dependent. Leuk Res (2005) 1.33
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
NOX enzymes and pulmonary disease. Antioxid Redox Signal (2009) 1.29
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol (2010) 1.28
Role of mitogen-activated protein kinases in 4-hydroxy-2-nonenal-induced actin remodeling and barrier function in endothelial cells. J Biol Chem (2003) 1.28
Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal (2008) 1.28
Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J (2005) 1.27
Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol (2008) 1.27
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One (2010) 1.25